Close Menu

NEW YORK – Cardea Bio and Nanosens Innovations — the companies that teamed up to develop a CRISPR-Cas9-based biosensor diagnostic device using a graphene transistor called the CRISPR-Chip — announced today that they are merging.

Nanosens will become a subsidiary of Cardea, and the companies plan to sell CRISPR-Chip technology-based products under the Nanosens brand. Kiana Aran — an assistant professor and principal investigator at the Keck Graduate Institute of Applied Life Sciences, and cofounder of Nanosens — will join Cardea as chief science officer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.